Research Studies
Back to Results
A Phase II, randomized, double-blind, study of the use of Rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer
Description
This is a phase II, randomized, double-blind, trial for the use of Rucaparib as maintenance therapy in metastatic and recurrent endometrial cancer.
Details
Age
Adult
Eligibility
Females aged 18-89 with primary stage III/IV or recurrent endometrial cancer whom have received at least one prior chemotherapy regimen and no more than two prior cytoxic regimens (including hormonal therapy).
Type of Study
Treatment
Locations
Fox Chase Cancer Center
University of Colorado Hospital
University of Pennsylvania
University of Pittsburgh Cancer Institute
Principal Investigator
Bradley Corr, MD
Study ID
Protocol Number: 18-0567
More information available at ClinicalTrials.gov: NCT03617679
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers